Trial reportDrug design, development and therapy2026
Efficacy of Remimazolam for Anesthesia in Patients Undergoing Renal Allograft Transplantation: A Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: As a novel benzodiazepine sedative, remimazolam has demonstrated favorable anesthetic properties. However, its clinical performance in patients undergoing renal allograft transplantation remains undetermined. This study aimed to evaluate the efficacy of remimazolam for anesthesia in patients undergoing renal allograft transplantation, with the incidence of hypotension during induction as the primary endpoint. Patients and Methods: Sixty patients scheduled for elective living-related renal transplantation were enrolled. The participants were randomly allocated into two groups (n=30 each): the propofol group (Group P) and the remimazolam group (Group R). Groups P and R received propofol and remimazolam, respectively, for anesthesia induction and maintenance. The patients' hemodynamic parameters, postoperative recovery outcomes, adverse reactions, and pharmacokinetic parameters of the sedative drugs were recorded and compared between groups. Results: Compared with propofol, remimazolam has a longer onset time, but provides better hemodynamic stability, more rapid metabolism, negligible injection pain, and no significant impact on hepatic or renal function. Conclusion: Despite its prolonged onset time, remimazolam provides better hemodynamic stability and less injection pain than propofol in patients undergoing allogeneic renal transplantation, with comparable recovery outcomes. Its rapid metabolism is evidenced by a prompt decline in plasma concentration following discontinuation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.